Search Results - "Vikse, Elisabeth Lea"

Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults by Tunheim, Gro, Fossum, Even, Robertson, Anna Hayman, Rø, Gunnar Øyvind Isaksson, Chopra, Adity, Vaage, John T, Vikse, Elisabeth Lea, Kran, Anne-Marte Bakken, Magnus, Per, Trogstad, Lill, Mjaaland, Siri, Hungnes, Olav, Lund-Johansen, Fridtjof

“…According to Norwegian registries, 91% of individuals ≥ 16 years had received ≥ 1 dose of COVID-19 vaccine by mid-July 2022, whereas less than 2% of children <…”
Get full text

Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022 by Vikse, Elisabeth Lea, Fossum, Even, Erdal, Magnhild Sekse, Hungnes, Olav, Bragstad, Karoline

“…New immune evasive variants of SARS‐CoV‐2 continue to emerge, potentially causing new waves of covid‐19 disease. Here, we evaluate levels of neutralizing…”
Get full text

A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery by Benjakul, Sopisa, Anthi, Aina Karen, Kolderup, Anette, Vaysburd, Marina, Lode, Heidrun Elisabeth, Mallery, Donna, Fossum, Even, Vikse, Elisabeth Lea, Albecka, Anna, Ianevski, Aleksandr, Kainov, Denis, Karlsen, Karine Flem, Sakya, Siri Aastedatter, Nyquist-Andersen, Mari, Gjølberg, Torleif Tollefsrud, Moe, Morten C, Bjørås, Magnar, Sandlie, Inger, James, Leo C, Andersen, Jan Terje

“…Immunocompromised patients often fail to raise protective vaccine-induced immunity against the global emergence of severe acute respiratory syndrome…”
Get full text